However, DPP inhibitors also promoted the recruitment of tumor-infiltrating CD45, MPO, F4/80, CD4, Foxp3-positive cells, and MDSC and decreased CD8-positive lymphocytes in metastatic sites in mouse breast cancer models by ROS-NF-κB-dependent NLRP3 inflammasome activation [57]. The gene discussed is NLRP3; the disease is breast cancer.